Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07252726
PHASE4

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Sponsor: Ottawa Hospital Research Institute

View on ClinicalTrials.gov

Summary

The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers. Participants with metastatic breast or prostate cancer will be randomly placed in one of two groups: a morning group and an evening group. The group assignment will determine whether they take their endocrine therapy in the morning or the evening. The primary outcome of this pilot study is to evaluate the feasibility of study procedures in order to conduct a larger definitive trial in the future. The secondary outcomes include comparing quality of life, tolerability, and efficacy outcomes between the morning and evening groups for each of the two cancer cohorts (metastatic breast and prostate cancer).

Official title: A Randomised, Multicentre Trial Evaluating the Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers (REaCT-CHRONO-MetBP Pilot Study)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-02-02

Completion Date

2033-03

Last Updated

2026-02-09

Healthy Volunteers

No

Interventions

OTHER

Morning administration of CDK4/6 inhibitor

Morning administration of cyclin-dependent kinase (CDK) 4/6 inhibitor defined as, within one hour of the participant wake up time.

OTHER

Evening administration of CDK4/6 inhibitor

Evening administration of cyclin-dependent kinase (CDK) 4/6 inhibitor defined as, within one hour of the participant bedtime.

OTHER

Morning administration of ARPI

Morning administration of androgen receptor pathway inhibitors (ARPI) defined as, within one hour of the patient wake up time.

OTHER

Evening administration of ARPI

Evening administration of androgen receptor pathway inhibitors (ARPI) defined as, within one hour of the patient bedtime.

Locations (3)

Waterloo Regional Health Network

Kitchener, Ontario, Canada

The Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada